Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979–2008
Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France. Epidemiology (Cambridge, Mass.)
(Impact Factor: 6.2).
03/2012; 23(2):301-7. DOI: 10.1097/EDE.0b013e3182448295
Some case-control studies have reported increased risks of glioma associated with mobile phone use. If true, this would ultimately affect the time trends for incidence rates (IRs). Correspondingly, lack of change in IRs would exclude certain magnitudes of risk. We investigated glioma IR trends in the Nordic countries, and compared the observed with expected incidence rates under various risk scenarios.
We analyzed annual age-standardized incidence rates in men and women aged 20 to 79 years during 1979-2008 using joinpoint regression (35,250 glioma cases). Probabilities of detecting various levels of relative risk were computed using simulations.
For the period 1979 through 2008, the annual percent change in incidence rates was 0.4% (95% confidence interval = 0.1% to 0.6%) among men and 0.3% (0.1% to 0.5%) among women. Incidence rates have decreased in young men (20-39 years) since 1987, remained stable in middle-aged men (40-59 years) throughout the 30-year study period, and increased slightly in older men (60-79 years). In simulations, assumed relative risks for all users of 2.0 for an induction time of up to 15 years, 1.5 for up to 10 years, and 1.2 for up to 5 years were incompatible with observed incidence time trends. For heavy users of mobile phones, risks of 2.0 for up to 5 years' induction were also incompatible.
No clear trend change in glioma incidence rates was observed. Several of the risk increases seen in case-control studies appear to be incompatible with the observed lack of incidence rate increase in middle-aged men. This suggests longer induction periods than currently investigated, lower risks than reported from some case-control studies, or the absence of any association.
Available from: Parviz Tajik
- "Cancer (IARC), has rated radiations from mobile phones in grade 2B, (available online at:< http://www.iarc.fr/en/media-centre/pr/2011/pdfs/pr208_E.pdf>. That means mobile phone radiation is a possible human carcinogen and mobile phone use could be associated with some risk of carcinogenicity (Deltour et al., 2012; Hardell et al., 2011; Hartikka et al., 2009; Little et al., 2012; Morgan, 2006). Mobile phone safety standards are usually set by regulatory bodies considering the thermal effects of the radiations from base stations and mobile handsets. "
[Show abstract] [Hide abstract]
ABSTRACT: Over the last decade, communication industries have witnessed a tremendous expansion, while, the biological effects of electromagnetic waves have not been fully elucidated. Current study aimed at evaluating the mutagenic effect of long-term exposure to 900-MHz radiation on alpha-Int1 gene sequences of Candida albicans. A standard 900 MHz radiation generator was used for radiation. 10 ml volumes from a stock suspension of Candida albicans were transferred into 10 polystyrene tubes. Five tubes were exposed at 4 °C to fixed magnitude of radiation with different time periods of 10, 70, 210, 350 and 490 hours. The other 5 tubes were kept far enough from radiation. The samples went under genomic DNA extraction. PCR amplification of alpha-Int1 gene sequence was done using one set of primers. PCR products were resolved using agarose gel electrophoresis and the nucleotide sequences were determined. All samples showed a clear electrophoretic band around 441 bp and further sequencing revealed the amplified DNA segments are related to alpha-Int1 gene of the yeast. No mutations in the gene were seen in radiation exposed samples. Long-term exposure of the yeast to mobile phone radiation under above mentioned conditions had no mutagenic effect on alpha-Int1 gene sequence.
Saudi Journal of Biological Sciences 05/2015; 32. DOI:10.1016/j.sjbs.2015.05.001 · 1.26 Impact Factor
Available from: dos.sagepub.com
- "Such classification was not supported, at least, by genotoxicity-based mechanism (Vijayalaxmi and Prihoda 2012). Furthermore, the overall brain cancer indices among the general population did not suggest an increasing trend after the introduction of mobile phones (Roosli et al. 2007; Inskip et al. 2010; de Vocht et al. 2011; Deltour et al. 2012). A more recent prospective study also revealed significantly decreased risk for glioma in mobile phone users (Benson et al. 2013). "
[Show abstract] [Hide abstract]
ABSTRACT: There is widespread concern among the general public regarding the ever increasing use of mobile phones. The concern is mainly because the antenna which transmits nonionizing radiofrequency fields is held close to the head during use and thus might cause brain cancer. By far, the largest epidemiological study was conducted by the INTER-PHONE study group and the results were published in 2011. The author's conclusions were (i) no increased risk of meningioma and glioma in mobile phone users and (ii) there were suggestions of an increased risk for glioma at the highest exposure levels but, bias and error prevented a causal interpretation. We have carefully examined all of the odd ratios presented in the INTERPHONE study publication: our results showed 24.3% decreased and 0.7% increased risk for meningioma and 22.1% decreased and 6.6% increased risk for glioma. Hence, we hypothesize that the overwhelming evidence for the decreased risk for both diseases may be due to the induction of 'adaptive response' which is well-documented in scientific literature.
Dose-Response 07/2014; 12(3):509-14. DOI:10.2203/dose-response.14-012.Vijayalaxmi · 1.22 Impact Factor
Available from: PubMed Central
- "Personal habits such as diet, alcohol use, caffeine intake, and nicotine use have been studied, but no clear association with GB has been identified. Multiple studies have also failed to correlate cell phone usage with tumor incidence.13,14 In the past 5 years, the role of cytomegalovirus genes in malignant gliomas has been explored. "
[Show abstract] [Hide abstract]
ABSTRACT: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics - particularly the use of O6-methylguanine-DNA methyltransferase status - affect clinical management.
Clinical Pharmacology: Advances and Applications 01/2013; 5(1):1-9. DOI:10.2147/CPAA.S26586
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.